Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04854941 |
|
Recruitment Status :
Completed
First Posted : April 22, 2021
Last Update Posted : January 28, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Coronavirus Infection | Other: Probiotics | Not Applicable |
A randomized controlled open-label study approved by the local ethical committee. The study included patients with COVID-19 admitted to the T.M. Tareev Clinic of Internal Diseases of I.M. Sechenov First Moscow State Medical University in whom the disease was confirmed using polymerase chain reaction on nasopharyngeal and oropharyngeal swabs to detect severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2). The study was conducted from December 2020 to March 2021 and included participants in the age range from 18 to 75 years.
The exclusion criteria were age over 75 years or under 18 years, consumption of probiotics for 3 months prior to admission, history of intolerance to probiotics or their components, refusal to participate and sign informed consent, pregnancy or breastfeeding, cancer or mental illness, and severe renal (glomerular filtration rate less than 50 mL/min) or hepatic (equivalent to cirrhosis class B or C on the Child-Pugh scale) dysfunction at the time of admission.
Patients who prematurely discontinued the consumption of probiotics for reasons not related to the development of side effects were excluded from the study.
The patients were randomised to the probiotics group (PRO group) or the control group (CON group). Patients in the PRO group received probiotics containing ~109 colony forming units (CFU) of Lactobacillus rhamnosus PDV 1705, ~109 CFU of Bifidobacterium bifidum PDV 0903, ~109 CFU of B. longum subsp. infantis PDV 1911, and ~109 CFU of B. longum PDV 2301 three times a day during the hospital stay but for no more than 14 days (PDV is the commercial letter designation of the bacterial strains). The end point of the trial was day 14 of hospitalisation or the day of the patient's discharge or death, whichever occurred earlier.
The control group consisted of patients who did not receive probiotics. Patients in both the groups also received dexamethasone and antiviral (favipiravir and/or riamilovir), antibacterial, anticoagulant (enoxaparin in most cases; rivaroxaban and dabigatran were used much less frequently), and anticytokine (tocilizumab or/and olokizumab) drugs according to indications and contraindications.
Death from any cause was considered the primary outcome. Duration of hospitalisation, total duration of the disease, incidence of admission to intensive care unit, need for oxygen support or mechanical ventilation, and changes in the values of key biomarkers were considered the main secondary outcomes. The duration of diarrhoea [loose or watery stools or an increase in the frequency of bowel movements (more than three times per day)] and incidence of hospital-acquired diarrhoea as well as the progression of pre-existing liver injury and onset of liver injury were considered additional secondary outcomes. Liver injury was determined through the presence of abnormalities in any of the main liver test findings (serum alanine transaminase, aspartate transaminase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, and albumin levels).
The volume of the affected lungs was measured using chest computed tomography (CT); it included the sum of ground glass and consolidation volumes.
Results are presented as the median [interquartile range]. The groups were compared using Mann-Whitney test for continuous data and chi-square test for categorical data. Wilcoxon test was used to assess the changes in continuous biomarker values. Mortality was assessed using the Kaplan-Meier estimator and Cox's test. A p value ≤0.05 was considered the criterion for significance. Statistical calculations were performed using "Statistica 10" soft (TIBCO Software inc, Palo Alto, CA)
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection |
| Actual Study Start Date : | December 10, 2020 |
| Actual Primary Completion Date : | March 10, 2021 |
| Actual Study Completion Date : | April 10, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Probiotics group (PRO)
99 patients with COVID-19 infection who have been supplemented with a Lactobacillus and Bifidobacterium containing probiotic in addition to standard regimen (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
|
Other: Probiotics
Probiotics (10^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks |
|
No Intervention: Control group (CON)
101 patients with COVID-19 infection who have been treated with standard regimen only (oxygen support, antiviral, antibacterial, anticoagulant, anticytokine (tocilizumab and olokizumab) drugs and dexamethasone treatment according to indications and contraindications)
|
- Mortality [ Time Frame: During hospitalization (Since the first day of hospitalization to the day of the patient's discharge) ]The number of died patients during hospitalization
- Duration of hospitalization [ Time Frame: Since the first day of hospitalization to the day of the patient's discharge ]The number of days patients stayed at hospital
- Total duration of the disease [ Time Frame: Since the first day of hospitalization to the day of the patient's discharge ]The number of days patients had complaints
- Incidence of admission to intensive care unit [ Time Frame: at the 14th day of hospitalization or at the day of the patient's discharge ]The number of patients admitted to the intensive care unit during hospitalization
- Need for non-invasive ventilation [ Time Frame: at the 14th day of hospitalization or at the day of the patient's discharge ]The number of patients requiring a non-invasive ventilation during hospitalization
- Days of non-invasive ventilation [ Time Frame: at the 14th day of hospitalization or at the day of the patient's discharge ]The number of days that patients had non-invasive ventilation during hospitalization
- Need for invasive ventilation [ Time Frame: at the 14th day of hospitalization or at the day of the patient's discharge ]The number of patients requiring an invasive ventilation during hospitalization
- Changes in the values of C-reactive protein level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of C-reactive protein level (mg/L) in serum of the patients during hospitalization
- Changes in the counts of white blood cells in blood test [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The counts of white blood cells (10^9/L) in blood test of the patients during hospitalization
- Changes in the counts of neutrophils in blood test [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The counts of neutrophils (10^9/L) in blood test of the patients during hospitalization
- Changes in the counts of lymphocytes [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The counts of lymphocytes (10^9/L) in blood test of the patients during hospitalization
- Changes in the counts of platelets [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The counts of platelets (10^9/L) in blood test of the patients during hospitalization
- Changes in the values of erythrocyte sedimentation rate in in blood test [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of erythrocyte sedimentation rate (mm/hr) in blood test of the patients during hospitalization
- Changes in the values of creatinine level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of creatinine (μmol/l) level in serum of the patients during hospitalization
- Changes in the values of alanine aminotransferase (ALT) level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of alanine aminotransferase (ALT) level (u/L) in serum of the patients during hospitalization
- Changes in the values of aspartate aminotransferase level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of aspartate aminotransferase (AST) level (u/L) in serum of the patients during hospitalization
- Changes in the values of albumen level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of albumen level (g/L) in serum of the patients during hospitalization
- Changes in the values of total bilirubin level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of total bilirubin level (μmol/l) in serum of the patients during hospitalization
- Changes in the values of lactate dehydrogenase level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of lactate dehydrogenase (LDH) level (u/l) in serum of the patients during hospitalization
- Changes in the values of ferritin level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of ferritin level (μg/l) in serum of the patients during hospitalization
- Changes in the values of fibrinogen level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of fibrinogen level (g/l) in serum of the patients during hospitalization
- Changes in the values of potassium level in serum [ Time Frame: at the first and at the 14th day of hospitalization (or at the first day and at day of the patient's discharge) ]The values of potassium level (mmol/l) in serum of the patients during hospitalization
- Incidence of diarrhoea [ Time Frame: at 14th day of hospitalization (or at the day of the patient's discharge) ]The number of patients with diarrhea (loose or watery stools or frequent bowel movements more than three times a day) during hospitalization
- The duration of diarrhoea [ Time Frame: at 14th day of hospitalization (or at the day of the patient's discharge) ]The number of days that the patients had diarrhea (loose or watery stools or frequent bowel movements more than three times a day)
- The maximum volume of the affected lungs [ Time Frame: at 14th day of hospitalization (or at the day of the patient's discharge) ]The volume of the affected lungs counted by the sum of ground glass and consolidation volumes (%) using chest computed tomography (CT)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with COVID-19 infection confirmed by polymerase chain reaction of nasopharyngeal and oropharyngeal swabs to the causative agent of this infection
- age from 18 to 75 years old from December 2020 to April 2021
Exclusion Criteria:
- the patient's decision to withdraw from the study
- refusing to take the probiotic for a reason not related to the development of side effects.
Non-inclusion criteria:
- age over 75 years old or under 18 years old,
- taking probiotics for 3 months prior to admission
- history of intolerance to probiotics or their components
- refusal to participate and sign informed consent
- pregnancy or breastfeeding
- presence of cancer or psychoemotional disorders
- renal failure at the time of admission (glomerular filtration rate less than 50 ml / min)
- hepatic failure at the time of admission (equivalent to cirrhosis class B or C on the Child-Pugh scale)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04854941
| Russian Federation | |
| I.M. Sechenov First Moscow State Medical University | |
| Moscow, Russian Federation, 119991 | |
Other Publications:
| Responsible Party: | I.M. Sechenov First Moscow State Medical University |
| ClinicalTrials.gov Identifier: | NCT04854941 |
| Other Study ID Numbers: |
PROCOV-19-2020 |
| First Posted: | April 22, 2021 Key Record Dates |
| Last Update Posted: | January 28, 2022 |
| Last Verified: | April 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | The provision of data is prohibited by Local Ethical Committee and is possible upon receipt of an official request addressed to the principal investigator |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Novel Coronavirus Infection Probiotics Lactobacillus Bifidobacterium Clinical outcomes |
C.difficile Diarrhea Liver mortality |
|
Infections Communicable Diseases Coronavirus Infections Disease Attributes Pathologic Processes |
Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Diseases |